INTRODUCTION
============

Chromatin is a highly common structure that contains DNA, histones, and other chromosomal proteins. The basic building block of chromatin is the nucleosome, which is made up of two copies of each histone: H2A, H2B, H3, and H4. The N-terminal tails of the histones are subject to posttranslational modifications (PTMs), which in turn affect numerous biological processes including transcription, replication, and chromosome maintenance. Methylation of the lysine residues within histones is regulated by methyltransferases (KMTs) and demethylases (KDMs) for the maintenance of cell fate and genomic stability. KDM3B, also known as JMJD1B, is a histone H3K9-specific demethylase. Its gene is located in the 5q31 chromosomal region in humans, which has often been found to be deleted in breast cancer [@B001] and myeloid leukemia [@B002]. KDM3B has been studied for regulation of the expression of the leukemic oncogene *lmo2* [@B003].

Angiogenesis, the process by which blood capillaries grow from the pre-existing vascular tree, is a key event in tumor growth and progression. Among the different growth factors which play roles in angiogenesis, VEGFA (vascular endothelial growth factor A) and its receptor are major mediators of tumor angiogenesis. Angiopoietin-1 (ANGPT1) is fundamental to physiological angiogenesis, including endothelial cell survival, vascular branching, and pericyte recruitment [@B004]. ANGPT1 binds to and activates the TEK/TIE2 receptor by inducing its dimerization and tyrosine phosphorylation, playing an important role in the regulation of angiogenesis [@B005], [@B006]. Overexpression of ANGPT1 has been proven to occur in malignant glioblastoma [@B007], [@B008], neuroblastoma [@B009], non-small cell lung cancer [@B010], and other tumors [@B004].

However, the role of ANGPT1 in tumor angiogenesis is less clear. Increasing amounts of experimental data have suggested that ANGPT1 contributes to the stabilization of newly organized blood vessels [@B011].

In the present study, we report that KDM3B negatively regulates *ANGPT1* transcription with its corepressor, SMRT, via recruitment to the *ANGPT1* promoter. This activity is independent of its demethylase activity, suggesting that KDM3B has a mechanism by which to repress transcription of the target gene *ANGPT1* to inhibit cellular proliferation and migration.

RESULTS
=======

Negative regulation of ANGPT1 transcription by KDM3B
----------------------------------------------------

Previously, we conducted global gene expression profiling of human erythroleukemic K562 cells stably expressing KDM3B shRNA in the Tet-on inducible expression system [@B003]. Among the differentially expressed genes, *ANGPT1* was found to be up-regulated when KDM3B was knocked down in the K562 cell line [@B003]. As a key regulator of angiogenesis, ANGPT1 binds to and activates the TEK/TIE2 receptor by inducing tyrosine phosphorylation. Since the transcriptional activation activity of KDM3B has been known to be conferred through H3K9 demethylation, we wanted to investigate the mechanism of the KDM3B-mediated negative regulation of *ANGPT1*. First, RT-PCR was performed on the K562 shKDM3B stable cell line to confirm the microarray data. As expected, the transcription of *ANGPT1* was up-regulated by KDM3B knock-down ([Fig. 1](#F001){ref-type="fig"}A). To further confirm the *ANGPT1* up-regulation induced by the depletion of KDM3B, RT-PCR was also conducted on 293T cells. Again, *ANGPT1* was increased in 293T cells when KDM3B was knocked down by transient transfection with KDM3B shRNA ([Fig. 1](#F001){ref-type="fig"}B).

![KDM3B represses *ANGPT1* expression. (A) K562 shKDM3B stable cells were analyzed by real time PCR to examine the mRNA expression level of *ANGPT1*. Results are shown as means ± SDs; n = 3. \*\*P ＜ 0.01. KDM3B knock-down was confirmed by western blot analysis. (B) shKDM3B transfected 293T cells were analyzed by real time PCR to examine the mRNA expression levels of *ANGPT1*. Results are shown as means ± SDs; n = 3. \*\*P ＜ 0.01. KDM3B knock-down was confirmed by western blot analysis. (C) GFP-KDM3B or GFP-KDM3B ΔC transfected 293T cells were analyzed by real time PCR to examine the mRNA expression levels of *ANGPT1*. Overexpression of KDM3B and KDM3B ΔC confirmed by western blot analysis. Results are shown as means ± SDs; n = 3. \*\*\*P ＜ 0.001.](BMB-48-401-g001){#F001}

To investigate whether KDM3B regulates *ANGPT1* through its demethylase activity, transfection was carried out with KDM3B or KDM3BΔC, in which demethylase activity of jmjC-domain was deleted. When KDM3B was overexpressed, significant decrease of *ANGPT1* was observed. Notably, *ANGPT1* was also decreased in cells overexpressing KDM3BΔC ([Fig. 1](#F001){ref-type="fig"}C). These results indicated that the KDM3B-mediated down-regulation of *ANGPT1* was independent of its demethylase activity.

Transcriptional regulation of *ANGPT1* by KDM3B
-----------------------------------------------

In order to determine the mechanism of *ANGPT1* down-regulation by KDM3B more precisely, a reporter assay was performed using the *ANGPT1* promoter-driven luciferase (luc) reporter system. Consistent with the results of microarray analysis, the transcriptional activity of *ANGPT1* was increased in a dose-dependent manner with the knockdown of KDM3B in 293T cells ([Fig. 2](#F002){ref-type="fig"}A). In addition, *ANGPT1* was decreased when KDM3B was overexpressed ([Fig. 2](#F002){ref-type="fig"}B). As mentioned above, KDM3B activates gene expression through the demethylation of H3K9me1/2. However, the regulation of *ANGPT1* indicated the opposite results. Thus, we hypothesized that other transcription factors were involved in the regulation of *ANGPT1*.

![KDM3B regulates *ANGPT1* transcription. (A and B) shKDM3B (A) or KDM3B (B) were co-transfected with the *ANGPT1* promoter-luc construct in 293T cell line. Cell extracts were then assayed for luciferase activity, which was normalized to β-galactosidase. Results are shown as means ± SDs; n = 3. \*\*\*P ＜ 0.001; \*\*P ＜ 0.01. (C and D) 293T cells were co-transfected with the indicated plasmids. Cell extracts were then assayed for luciferase activity, which was normalized to β-galactosidase. Results are shown as means ± SDs; n = 3. \*\*\*P ＜ 0.001; \*P ＜ 0.05.](BMB-48-401-g002){#F002}

Having established that KDM3B negatively regulates the transcription of *ANGPT1*, we next searched for any transcription factor which is involved in the KDM3B-mediated transcriptional regulation. Transcription factors known for their roles in angiogenesis were screened, such as JunB, and GATA1. Each transcription factor was then tested in *ANGPT1* transcriptional activity reporter analysis.

As shown in [Fig. 2](#F002){ref-type="fig"}C, KDM3B knockdown increased *ANGPT1* transcription, which was further increased by the addition of JunB ([Fig. 2](#F002){ref-type="fig"}C). Similar results were obtained when another transcription factor, GATA1, was added ([Fig. 2](#F002){ref-type="fig"}D). These results indicated that JunB and GATA1 are involved in the transcriptional activation of *ANGPT1*. However, further activation of the *ANGPT1* promoter activity despite KDM3B-mediated transcriptional repression suggests that JunB and GATA1 regulate *ANGPT1* via a different pathway from KDM3B.

KDM3B interacts with corepressor SMRT
-------------------------------------

Since our results indicated that KDM3B functions as a transcriptional repressor for *ANGPT1*, we decided to investigate whether KDM3B works in concert with corepressors such as HDAC, NcoR, or SMRT to repress *ANGPT1*. To accomplish this, transient transfection and Immunoprecipitations assays were conducted. These assays clearly showed that SMRT, but not HDAC or NcoR1 (data not shown), strongly interacted with KDM3B, suggesting that KDM3B and SMRT form a repressor complex during *ANGPT1* transcription ([Fig. 3](#F003){ref-type="fig"}A). To further test the SMRT-mediated KDM3B activity, reporter assays were carried out to investigate whether KDM3B works together with SMRT. As expected, overexpression of both wild type KDM3B and that with the jmjC-domain deleted repressed *ANGPT1* transcription ([Fig. 3](#F003){ref-type="fig"}B). When cells were cotransfected with KDM3B and SMRT, *ANGPT1* transcription was further downregulated ([Fig. 3](#F003){ref-type="fig"}B). However, when cells were cotransfected with KDM3B and shSMRT, downregulation of *ANGPT1* was recovered ([Fig. 3](#F003){ref-type="fig"}B). Next, we knocked down KDM3B with shRNA and *ANGPT1* transcription was upregulated ([Fig. 3](#F003){ref-type="fig"}C). Furthermore, when cells were cotransfected with shKDM3B and shSMRT, *ANGPT1* transcription was further upregulated ([Fig. 3](#F003){ref-type="fig"}C). These results suggest that KDM3B and SMRT form a corepressor complex and negatively regulate *ANGPT1* transcription.

![KDM3B interacts with corepressor SMRT. (A) 293T cells were co-transfected with Flag-KDM3B and pCMX-SMRT prior to immunoprecipitation with anti-Flag antibodies. Immunoprecipitated and associated proteins were eluted, resolved by SDS-PAGE, and immunoblotted with anti-Flag and anti-SMRT antibodies. (B and C) 293T cells were co-transfected with the indicated plasmids. Cell extracts were then assayed for luciferase activity, which was normalized to β-galactosidase. Results are shown as means ± SDs; n = 3. \*\*\*P ＜ 0.001; \*P ＜ 0.05.](BMB-48-401-g003){#F003}

Increase of cell motility by depletion of KDM3B
-----------------------------------------------

Previous studies reported induction of *ANGPT1* increase cell proliferation, wound healing, and invasion [@B006], [@B012]-[@B014]. To further investigate the physiological effects of the KDM3B- mediated transcriptional regulation of *ANGPT1*, we first conducted the cell proliferation assay ([Fig. 4](#F004){ref-type="fig"}A). When KDM3B was overexpressed, a decrease in cell proliferation was observed. However, cellular proliferation was significantly increased when KDM3B was knocked down.

![Depletion of KDM3B induces cell proliferation and motility. (A) Proliferation was monitored over 72 h in 293T cells expressing Flag-KDM3B or shKDM3B. (B) Photomicrographs from a scratch-motility assay of MCF7 expressing Flag-KDM3B or shKDM3B for 24 h (Left panel). Percent of the gap distance closed between the two migrating form fronts was measured and shown as a graph (Right panel). Results are shown as means ± SDs; n = 3. \*P ＜ 0.05; \*\*P ＜ 0.01.](BMB-48-401-g004){#F004}

Previous studies suggested that ANGPT1 contributes to angiogenesis by stabilizing blood vessel maturation [@B011]. A scratch-motility assay was then performed using 293T cells transiently expressing KDM3B or shKDM3B with either control pCMV-3X-flag or shCTL. The closure of wounded areas was observed to be significantly accelerated in KDM3B knock-down cells suggesting that KDM3B plays a role in the repression of cell motility, probably via regulation of *ANGPT1* ([Fig. 4](#F004){ref-type="fig"}B). As expected, the closure of wounds was decelerated when KDM3B was overexpressed. These results indicated that increase of *ANGPT1* induced by knock-down of KDM3B may have regulated cell motility in our assay. Collectively, our findings indicate that angiogenesis-mediated wound healing is regulated through the involvement of a subset of KDM3B target genes exemplified by *ANGPT1*, and thereby affects cell proliferation and cell motility properties.

DISCUSSION
==========

KDM3B is a H3K9me1/2 demethylase, and is highly expressed in hematopoietic cells [@B015]. H3K9 methylation status is linked to heterochromatin formation and the silencing of target genes [@B016], [@B017]. Herein, we attempted to elucidate the negative regulation of *ANGPT1* transcription by KDM3B. Consistent with our previous microarray analysis, depletion of KDM3B increased the expression of *ANGPT1*. By reporter assay using the *ANGPT1* promoter, it was found that *ANGPT1* promoter activity was up-regulated when KDM3B was knocked down. The negative regulation of *ANGPT1* by KDM3B was demonstrated to be independent of the H3K9 demethylase activity of KDM3B. There have been reports that G9a positively regulates the transcription mediated by various nuclear receptors through an HMTase-independent mechanism [@B018], [@B019]. Previously, we reported that H3K9 HMTase G9a activates the transcription of p21 in p53-null H1299 cells independent of its HMTase activity [@B020]. These reports, including the current study, indicate that there are different layers of regulatory networks in epigenetic modifiers, including HMTases and histone demethylases. It is also interesting that up-regulation of the *ANGPT1* transcription level was independent of angiogenesis-related transcription factors such as JunB and GATA1, tested herein. Further studies will be needed to elucidate the fine mechanism of transcriptional regulation by KDM3B, including identification of the responsible transcription factors involved.

Furthermore, we found that wound healing and invasion were increased by the knock-down of KDM3B. These results indirectly suggest that KDM3B plays a role in cell migration and proliferation. In conclusion, depletion of KDM3B increased the transcription of *ANGPT1*. Down-regulation of ANGPT1 was independent of the demethylase activity of KDM3B, and the SMRT corepressor plays role in the transcriptional repression of *ANGPT1* by KDM3B.

MATERIALS AND METHODS
=====================

Cell culture and transient transfection, RNA isolation and real-time PCR, Western blot analysis, Immunoprecipitation, and Statistical analysis are described in the online data supplement, available at <http://www.bmbreports.org/>.

Luciferase assay
----------------

293T and HCT116 cells were seeded at the density of 6 × 10^4^ cells in 48-well plates and transfected with pGL3-ANGPT1 promoter (100 ng), shKDM3B (200 ng or 400 ng), shSMRT (300 ng), GFP-KDM3B (100 ng or 200 ng), pCMV10-Flag-*lmo2* (100 ng), and pCMX-PL1-JunB (50 ng) using PEI. After 48 h of transfection, the cells were collected and lysed in cell culture lysis reagent. Luciferase activities were then determined by adding 10 μl of luciferase assay substrate into 70 μl of cell lysates, then measuring using a Glomax luminometer (Promega). The results were confirmed by performing each experiment at least in triplicate.

MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay
-----------------------------------------------------------------------

293T cells were seeded in 48-well plates (8 x 10^4^ cells/well) and transiently transfected with pCMV10-Flag-KDM3B and shKDM3B. After 0-4 days of incubation at 37℃, 20 μl of MTT (1 mg/ml) was added to the each well and incubated for an additional 4 h at 37℃, followed by aspiration of the medium and addition of 200 μl of dimethyl sulfoxide (DMSO). OD values were determined with an ELISA reader (Biochrom) at the wavelength of 570 nm. DMSO alone was measured as the blank and subtracted from all values to correct for background in the measurements.

Wound healing assay
-------------------

Cells were seeded in 24-well plates and transfected with pLKO.1 and shKDM3B. Twenty four hours after transfection, the cells were located in monolayers, and were scratched once with medium using a pipette tip to obtain a \"scratch\" in each well. Cells were then washed once with medium. Migration was monitored every 12 h, and photomicrographs were taken at each time point.
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